Skip to site menu Skip to page content

Daily Newsletter

14 November 2024

Daily Newsletter

14 November 2024

Nihon Kohden expands neurology portfolio with Ad-Tech Medical acquisition

Ad-tech’s portfolio consists of neurology electrode devices used for EEG monitoring, brain mapping, stereoelectroencephalography, and brain stimulation.

Phalguni Deswal November 13 2024

Nihon Kohden has expanded its portfolio of neurology electrode devices by acquiring a 71.4% stake in NeuroAdvanced Corp., the parent company of Ad-Tech Medical Instrument Corporation.

The Japanese company noted that acquisition “Nihon Kohden’s established expertise in electro encephalograph (EEG) systems with Ad-Tech’s specialized electrodes, strengthening the company’s ability to support comprehensive epilepsy care.”  

Archimed, an investment firm and previous owner of Ad-Tech, has the remaining stake in Ad-Tech and will act as a minority joint venture partner with Nihon Kohden. The acquisition is estimated to cost approximately ¥16bn ($103.66m).

GlobalData estimates that the global neurology device market is expected to expand from being worth approximately $13.1bn in 2024 to over $20.8bn by 2033. The neurological diagnostic and monitoring equipment device segment is expected to grow from $1.5bn to over $1.7bn over the same period.

Nihon Kohden noted that the acquisition is part of the company’s long-term BEACON 2030 vision. As part of FY2023 H1 financial statement, the company stated that as part of Phase II of BEACON 2030 vision it plans to make research and development (R&D) investments in patient monitors, ventilators, and Digital Health Solutions. The R&D investments total approximately ¥23.5bn ($152m).

“This acquisition represents a pivotal step in advancing critical solutions for epilepsy care,” said Roy Sakai, President of Nihon Kohden America. “By uniting our strengths, we’re enhancing our ability to provide end-to-end support for epilepsy—from accurate diagnosis to advanced interventions.”

Adding that this collaboration helps support these solutions for patients in acute neurocritical care situations, preserving function and enabling precision with intraoperative neuromonitoring (IONM) and enhancing usefulness of patient data using its analytics and digital health solutions (DHS).

Nihon Kohden’s portfolio consists of diagnostics systems such as EEG, electrocardiograph (ECG), automated haematology analysers, patient monitors, and treatment equipment including defibrillator, and pacemakers.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close